Certolizumab pegol subcutaneous PK
A reduced subcutaneous PK model representing certolizumab pegol absorption from a depot, systemic elimination, blood concentration, and cumulative exposure.
- Therapeutic
- Certolizumab pegol
- Target
- TNF / TNFA, P01375
- Disease
- Psoriasis
Biological model
A reduced subcutaneous PK model representing certolizumab pegol absorption from a depot, systemic elimination, blood concentration, and cumulative exposure.
Intervention
Certolizumab pegol
Biological focus
TNF / TNFA, P01375
Context
Psoriasis
Model details
A reduced subcutaneous PK model representing certolizumab pegol absorption from a depot, systemic elimination, blood concentration, and cumulative exposure.
Modeled states
- auc mg day lmg*day/L
Modeled dynamic state for auc mg day l.
- blood mgmg
Modeled dynamic state for blood mg.
- depot mgmg
Modeled dynamic state for depot mg.
- elapsed dayday
Modeled dynamic state for elapsed day.
Key readouts
- Blood certolizumab concentrationunknown
Model-derived readout for blood certolizumab concentration.
- Cumulative certolizumab exposuremg*day/L
Model-derived readout for cumulative certolizumab exposure.
- Apparent half-lifeunknown
Model-derived readout for apparent half-life.
- Blood certolizumab concentrationunknown
Model-derived readout for blood certolizumab concentration.
- blood mgmg
Model-derived readout for blood mg.
Explore this model
Choose a starting point to view its result. Adjust key model inputs when you want to explore a different outcome.
400 mg single-dose PBPK
How do loading and maintenance regimens shape certolizumab pegol blood concentration and exposure? Explore this intervention regimen through Blood certolizumab concentration, Cumulative certolizumab exposure, Apparent half-life. This is a mechanistic product exploration, not a paper-result reproduction.
Questions to explore
- How do loading and maintenance regimens shape certolizumab pegol blood concentration and exposure?
Starting result
This result reflects the starting settings. Run your changes to update it.
Model inputs
Five scientist-facing controls at most.
Compare a parameter
How does one model input change the response?
How do loading and maintenance regimens shape certolizumab pegol blood concentration and exposure?
bioavailability fraction
Model parameter controlling bioavailability fraction.
Exploratory range around the default value.
5 evenly spaced values in dimensionless. Other model inputs and the simulation window stay fixed.
Interpret with care
- Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.
- Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario.
Review the server-confirmed fixed price before starting the comparison.
Comparative response
End-of-window response across the selected parameter values.
Choose an exploratory range around the default, review the fixed price, and run the comparison.
Scientific reference
Supporting publication
A quantitative systems pharmacology model for certolizumab pegol treatment in moderate-to-severe psoriasisFrontiers in Immunology
